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Abstract
Background: TGFß overproduction in cancer cells is one of the main characteristics of late tumor progression being
implicated in metastasis, tumor growth, angiogenesis and immune response. We investigated the therapeutic efficacy of
anti-TGFß peptides in the control of angiogenesis elicited by conditional over-expression of TGFß.
Methods: We have inserted in human MCF7 mammary-cancer cells a mutated TGFß gene in a tetracycline-repressible vector
to obtain conditional expression of mature TGFß upon transient transfection, evaluated the signaling pathways involved in
TGFß-dependent endothelial cells activation and the efficacy of anti-TGFß peptides in the control of MCF7-TGFß-dependent
angiogenesis.
Results: TGFß over-expression induced in MCF7 several markers of the epithelial-to-mesenchymal transition. Conditioned-
medium of TGFß-transfected MCF7 stimulated angiogenesis in vivo and in vitro by subsequent activation of SMAD2/3 and
SMAD1/5 signaling in endothelial cells, as well as SMAD4 nuclear translocation, resulting in over-expression of the pro-
angiogenic growth and differentiation factor-5 (GDF5). Inhibition or silencing of GDF5 in TGFß-stimulated EC resulted in
impairment of GDF5 expression and of TGFß-dependent urokinase-plasminogen activator receptor (uPAR) overproduction,
leading to angiogenesis impairment. Two different TGFß antagonist peptides inhibited all the angiogenesis-related
properties elicited in EC by exogenous and conditionally-expressed TGFß in vivo and in vitro, including SMAD1/5
phosphorylation, SMAD4 nuclear translocation, GDF5 and uPAR overexpression. Antagonist peptides and anti-GDF5
antibodies efficiently inhibited in vitro and in vivo angiogenesis.
Conclusions: TGFß produced by breast cancer cells induces in endothelial cells expression of GDF5, which in turn stimulates
angiogenesis both in vitro and in vivo. Angiogenesis activation is rapid and the involved mechanism is totally opposed to
the old and controversial dogma about the AKL5/ALK1 balance. The GDF-dependent pro-angiogenic effects of TGFß are
controlled by anti-TGFß peptides and anti-GDF5 antibodies, providing a basis to develop targeted clinical studies.
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Introduction
Transforming growth factor beta-1 (TGFß), a multifunctional
cytokine initially identified as a ‘‘transforming’’ growth factor by its
property to induce malignant behaviour of normal fibroblasts in
culture [1], was later shown to promote profound growth-
suppressive effects on many cells and was therefore taken into
consideration as a candidate tumor suppressor gene [2,3].
However, it was soon discovered that metastasis of many different
types of tumors actually requires TGFß activity and that, in the
context of advanced disease, it has prooncogenic effects [4]. The
current understanding of the role of TGFß in cancer indicates that
TGFß suppresses the progression of early lesions, but later this
effect is lost and cancer cells themselves produce TGFß that
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promotes the metastatic process [5]. TGFß inhibits mammary
tumorigenesis by directly inducing mammary epithelial cells to
stop cell cycle, to undergo apoptosis and to release a complex
array of cytokines, growth factors and extracellular matrix proteins
that maintain mammary tissue homeostasis [6,7]. The events
related with the acquisition of malignancy-related properties by
TGFß identify a critical phase of tumor progression, which has
been named ‘‘TGFß-switch’’ [5,8], connoted by loss of TGFß-
dependent growth inhibition, apoptosis and genomic stability, and
by increased expression/activation of TGFß (reviewed in refs.
[8,9]) which profoundly affects tumor cells and their microenvi-
ronment. Accordingly, in breast cancer higher levels of TGFß are
often detected in tumors when compared to corresponding normal
mammary gland, and the difference appears even higher in the
most advanced stages of mammary tumor progression [10],
producing a micro-environment that promotes tumor growth,
epithelial-mesenchymal transition (EMT), survival and invasion/
motility of cancer cells, modulation of a set of pro-metastatic genes
that govern the pattern of osteoclast activation in the sites of bone
colonization of cancer cells [11], immuno-suppression and
angiogenesis [12,13].
Also angiogenesis regulation reflects the opposite activities of
TGFß. The effect of TGFß on angiogenesis has been shown to be
context-dependent [14,15]: at low concentrations TGFß promotes
endothelial cells (EC) proliferation and migration, whereas at high
concentration it has the opposite effect [14–17]. In bovine
capillary EC, TGFß signaling converts the VEGF/VEGF
receptor-2 (flk-1)-mediated activation of p38MAPK into a pro-
apoptotic signal [18], while protracted treatment of the same EC
with TGFß results into EC remodeling and induction of cord-like
structures [19]. TGFß has been shown to induce expression of
selected members of the VEGF family in EC [20] and carcinoma
cells [21]. Knockouts for TGFß and its receptors show defects in
angiogenesis, and often die in utero [22]. In conclusion, TGFß acts
either as inhibitor or enhancer of neo-vascularization in many
tumors, including breast cancer [6].
The opposing effects of TGFß on angiogenesis have been
explained by the differential involvement of two distinct signalling
cascades. TGFß can bind to and signal through two different type-
I receptors in EC, the ubiquitous TGFBR1 activin-like receptor
kinase 5 (ALK5) and the EC-restricted ACVRL1 (ALK1),
resulting in activation of SMAD2/3 and SMAD1/5, respectively
[14,15,23]. Through ALK5 TGFß determines the terminal
maturation phase of angiogenesis [24–26], while ALK1 stimulates
EC proliferation and migration [27]. Therefore, while the
ubiquitous ALK5 has a role in vascular maturation, the EC-
restricted ALK1 promotes neo-angiogenesis. It was thus suggested
that the balance between TGFß/ALK1 versus TGFß/ALK5 will
determine the pro- or anti-angiogenic effects of TGFß. However,
gain-of-function studies have shown that ALK1 signaling inhibits
proliferation and migration of human microvascular EC, implying
an involvenment of ALK1 in the resolution phase of angiogenesis
[28]. Further, similar to TGFß, another member of the TGFß
family, the bone morphogenetic protein 9 (BMP9), is a high-
affinity ligand for ALK1 in EC and exhibits both anti-angiogenic
[29,30] and pro-angiogenic effects on Matrigel plug vasculariza-
tion and in a xenograft model of pancreatic cancer [31].
Nevertheless, TGFß and BMP9 have been shown to synergize in
improving EC response to angiogenic FGF2 and VEGF stimula-
tion [32]. Within this complex scenario, the effects of TGFß on
tumor angiogenesis seem to be referred to direct stimulation of the
ALK1-SMAD1/5 signaling in EC of the tumor microenvironment
[12,33], or to promotion of VEGF expression [20,34]. We have
recently reported that TGFß at low concentrations (1 ng/ml)
exerts an angiogenic activity on microvascular EC in a Matrigel
model system, both in vitro and in vivo, by up-regulating urokinase-
type plasminogen activator (uPA) receptor (uPAR) expression [17].
Because of all these considerations, in the present work we have
used anti-TGFß peptides to blunt the pro-angiogenic activity of
the MCF-7 breast cancer cell line transfected with a TGFß gene
under the control of a tetracycline repressed CMV promoter (Tet-
Off system). We have observed that TGFß promotes angiogenesis
by inducing EC overproduction of the pro-angiogenic growth and
differentiation Factor-5 (GDF5) (also called Bone Morphogenetic
Protein-14, BMP14), which controls uPAR up-regulation in EC.
Two peptides, previously used in another study of our laboratory
[17], inhibited breast tumor TGFß-dependent angiogenesis in vitro
and in vivo by inhibition of TGFß signaling and of the subsequent
TGFß-dependent GDF5 overproduction in EC.
Materials and Methods
Ethics Statement
The local Institutional Animal Care and Use Committee of the
Medicine Faculty of Florence (Ospedale di Careggi) and the
Italian Ministry of Health (Ministerial Decree n 21/2010, released
on January 28, 2010) approved the experimental protocols
described in the study.
Cell Lines
Human dermal microvascular endothelial cells (MVECs) were
purchased from Lonza Ltd. Cells were maintained in complete
endothelial cell growth medium (ECGM), as described [35,36].
MVECs were used between the third and seventh passage in
culture. The breast cancer MCF7 Tet-Off Avanced cell line (BD
Clontech, Inc.) was grown in DMEM supplemented with 10%
fetal bovine serum, 1% penicillin-streptomycin, and 100 mg/ml
Geneticin (G418; all supplied by Life Technologies, Inc.).
Antagonist TGFß peptides
We have used two TGFß antagonist peptides developed by
Digna Biotech (Pamplona, Spain), one derived from its type III
receptor [37]: peptide p144 (TSLDASIIWAMMQN,
1580.86 Da); the other one derived from phage display library
technology [38]: peptide p17 (KRIWFIPRSSWYERA,
1995.6 Da). While p17 is water soluble, p144 is partially
hydrophobic. The final concentration of 100 mg/ml antagonist
peptides was chosen on the basis of previous results [17,37,38].
TGFß construct
The construct pTRETGF-beta1 containg the TGFß1 coding
sequence mutated at codon 223 (CysRSer) and 225 (CysRSer) in
pTRE2pur plasmid (Clontech) was produced in collaboration with
PRIMM srl, Milan, Italy. Briefly the TGFß1 sequence was
synthesized with Right GeneH technology using the optimal codon
usage for Homo sapiens. The synthetic gene, producing an activated
TGFß1, was inserted into the BamHI and NotI restriction site of
the pTRE2pur vector.
Transient Transfection
The cDNA-containing vector and the empty plasmid were
transiently transfected into MCF7 Tet-Off Advanced cells using
Lipofectamine Tranfection Reagents (Invitrogen Co.), according
to the manufacturer’s protocol. Briefly, 3.56105 cells/well were
plated in six multiwell plates 24 hrs before transfection. 24 hrs
after transfection, complete medium was replaced, supplemented
or not with 1 mg/ml of doxycycline.
TGFß Inhibitor Control Cancer Angiogenesis
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Measurement of TGFß levels in conditioned-medium
from Mock and TGFß transfected cells
Levels of TGFß in Mock and TGFß-transfected MCF7 (MCFM
and MCFTß, respectively) media were measured by a commercial
ELISA kit (eBioscence; Austria) according to the manufacturer
protocol. Determinations were done in quadruplicate and were
expressed as pg/ml.
Preparation of Conditioned-Media
Multi-well plates (6 wells) of MCFM and MCFTß were washed
with PBS and maintained 72 hours in 2 ml culture medium
supplemented with 2% fetal bovine serum, in the presence or in
the absence of doxycycline. The conditioned-medium (CM) was
then subjected to TGFß determination and properly diluted for in
vitro capillary morphogenesis and Western blot analysis.
Invasion assay
The Boyden chamber assay, where upper and lower wells were
separated by a porous membrane coated with Matrigel, was used
to evaluate cell invasion as described [35]. A total of 105 MCFM
or MCFTß cells were placed in the upper chamber in culture
medium added with 2% fetal calf serum and migration was
allowed to occur for 24 hours at 37uC in 5% CO2. Mobilization
was measured by counting the number of cells moving across the
filter. Each point was performed in triplicate. Migration was
expressed as the number of migrated cells 6 SD.
Cell Viability Assay
The viability of MCFM and MCFTß cells was determined by a
cell proliferation assay using WST-1 reagent (Roche). WST-1 is a
water-soluble sulfonated tetrazolium salt that is cleaved by cellular
succinate-dehydrogenases in living cells, yielding dark blue
formazan. Damaged or dead cells exhibit reduced or no
dehydrogenase activity. Briefly, Tet-Off MCFM and MCFTß
cells 24 hours after transfection were plated onto a 96-multiwell
plate in quadruple. After 24, 48 and 72 hours WST-1 solution/
culture medium (5 mmol/l, 1:9) was added to each well. Following
2-hours incubation at 37uC, absorbance at 450 nm (reference at
630 nm) was measured by a Multiskan JX microplate reader.
Percentage of cell viability was calculated based on the absorbance
measured relative to that of the untreated control cells maintained
in culture medium alone.
In vitro capillary morphogenesis assay
Capillary morphogenesis experiments on Matrigel were per-
formed as previoiously described [35] by plating 606103 MVECs/
well. Capillary morphogenesis was evaluated after 6 and 18 hours
using an inverted microscope (Leitz DM-IRB) equipped with
CCD optics and a digital analysis system (Image J 1.44 software,
NIH, Bethesda, MD). Some experiments were performed in the
presence of anti-GDF5 or anti-BMP7 antibodies (GeneTex), as
well as with irrelevant IgGs. Results were quantified by measuring
the extent of field occupancy of capillary projections (expressed as
the mean percentage 6SD, relative to control values set at 100%).
Six-to-nine photographic fields from 3 plates were scanned for
each point. Some experiments were performed in the presence of
5 mg/ml anti-GDF5 or irrelevant mouse IgG.
In vivo Matrigel Sponge Assay
An amount of 2.56106 MCFM or MCFTß, was injected
subcutaneously in 6–8 weeks old SCID mice (Charles River). Cell
suspensions were added to un-polymerized Matrigel at 4uC
containing 50 U/ml heparin at a final volume of 0.6 ml. The
Matrigel suspension was injected subcutaneously into the flanks of
4 mice for each condition (two plugs/mice) using a cold syringe. At
body temperature, the Matrigel polymerizes to a solid gel, which
becomes vascularized within 4 days in response to pro-angiogenic
substances. Pellets were removed and photographed. One pellet
from each mouse was formalin-fixed for immunohistochemistry.
The pellet was minced, and diluted in water to measure the
haemoglobin content with a Drabkin reagent kit (Sigma). Similar
experiments were performed also in the presence of the TGFß
antagonist peptides p17, p144 or of a scramble peptide (Digna
Biotech, Pamplona, Spain) [17] added to the Matrigel mix at final
concentration of 100 mg/ml. In other experiments p17 was
administered daily to mice by an intraperitoneal injection of
100 ml of a 1 mg/ml solution, until a total amount of 500 mg/
animal was reached. Further, sponge vascularization was evalu-
ated in C57/BL6 male mice injected with Matrigel containing CM
of MCFTß cells obtained after doxycycline subtraction, with or
without GDF5-siRNA or not targeting-siRNA, combined with
DharmaFECT.
Immunohistochemistry to evaluate matrigel sponge
vessel density
After fixation in formalin, the sponge specimens were embedded
in paraffin. Serial sections were stained with H&E or with a
primary rabbit polyclonal anti-CD31 IgG (ab28364, abcam
United Kingdom, dilution 1:50), following routine immunohisto-
logical methods: HRP-conjugated secondary IgG (Sigma-Aldrich,
1:200, 30 min) was revealed with 3,39-Diaminobenzidine as
chromogen (5 minutes), using hematoxyline as counterstain.
Counting of CD31-positive vessel structures was performed with
a 400-time magnification using a squared reference grid. Vessel
counting was performed in ten to fifteen fields. Statistical
significance of the different vessel counts was determined using
Student’s t-test where p#0.05 was considered statistically signifi-
cant.
Western Blot Analysis
Conditioned-media of MCF7 cells (100 ml) and aliquots of
MCF7 and MVECs lysates (50 mg) were obtained, processed, and
blotted as described [35,39]. The primary antibodies were: anti-
Vimentin (1:1000) (Sigma-Aldrich), anti-E-cadherin (1:500), anti-
N-cadherin (1:500) (Santa Cruz), anti-TGFß (1:250, catalog n. sc-
146; Santa Cruz); anti-phospho-SMAD1/5 (p-SMAD 1/5) (1:500,
catalog n. 9516), anti-SMAD5 (1:500, catalog n. 9517), SMAD2/3
(100 mg/ml, 1:500; catalog n. 3102), and phospho-SMAD2 (Ser
465/467) (p-SMAD 2) (100 mg/ml, 1:500) (catalog n. 3108) (all
from Cell Signaling Technology, Inc.), anti-GDF5 (650 mg/ml,
1:1000; catalog n. GTX113580; GeneTex) and anti–alpha
Tubulin (1:1000, catalog n. 3931; Sigma-Aldrich). uPAR expres-
sion in MVECs was evaluated by anti-uPAR M2 (1 mg/ml, rabbit
polyclonal antibody), kindly provided by Dr. D’Alessio (DIBIT,
San Raffaele Scientific Institute, Milan, Italy), previously used in
our laboratory [39]. Also MCF7 apoptosis was evaluated by
Western blot, using a monoclonal anti-caspase-3 (100 mg/ml,
1:500) (cat. Sc-7272, Santa Cruz). Protein-antibody complexes
were revealed by an Odyssey Infrared Imaging System, using
IRDye 800 CW goat antimouse IgG (1:12,000, cat. FE30926220;
LI-COR Biosciences) and Alexa Fluor 680 goat antirabbit IgG
(1:12,000, cat. A21076; Invitrogen) as fluorescent secondary
antibodies according to the instructions provided by the manu-
facturers.
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Immunofluorescence confocal microscopy
Immunofluorescence was performed as previously described
[39]. Mock and TGFß-MCF7 Tet-Off cells were placed on
coverslips in DMEM-10% FCS, fixed in paraformaldehyde and
permeabilised according to routine methods. The primary
antibodies were: anti-Vimentin (1:1000) (Sigma-Aldrich), anti-E-
cadherin (1:500), anti-N-cadherin (1:500) (Santa Cruz). Secondary
antibodies were anti-Rabbit IgG (whole molecule)-Cy3 conjugated
(1:1000) (Sigma-Aldrich), anti-Mouse IgG (whole molecule)-FITC
conjugated. MVECs were grown on coverslips in ECGM that
after 24 h was replaced with CM with or without the TGFß
antagonist peptides. After 1 and 2 hours MVECs were fixed and
permeablised. The anti-human primary antibody was anti-
SMAD4 (1:200) (catalog n. 3102; Cell Signaling), the secondary
antibody was CY3-conjugated anti-mouse IgG (1:800) (catalog n.
C2181, Sigma). For nuclear staining, the samples were incubated
with DAPI (2 mg/ml), for 15 min. Coverslips were observed under
a Bio-Rad MRC 1024 ES Confocal Laser Scanning microscope
(Bio-Rad, Hercules, CA). A single composite image was obtained
by superimposition of 20 optical sections (thickness of 1 mm at
intervals of 0.8 mm for each sample). Collected images were
analyzed by ImageJ software (NIH, Bethesda, MD).
Quantitative RT-PCR array for TGFß pathways activation
Total RNA was prepared using Nucleospin RNA II (Macherey-
Nagel, Germany), agarose gel checked for integrity, and reverse
transcribed with iScript cDNA Synthesis Kit (Bio-rad, ) using
random primers according to manufacturer’s instructions. The
StellArray system (LONZA Ltd., Switzerland), a qPCR based
assay in 96 well format was used for quantitative profiling of a set
of 94 preselected genes related to TGFß pathway. For comparison
of the quantitative gene expression profiles of cells under different
culture conditions, fold changes above and below 3 of analyzed
genes were plotted. Ct values were analyzed by Global Pattern
Recognition (GPR) data analysis tool (Bar Harbor Biotechnology,
USA) [40].
siRNA treatment
MVECs were transfected with 40 nM GDF5-siRNA, BMP7-
siRNA, or control not-targeting siRNA (Dharmacon) using
Lipofectamine 2000. After 48 h treated cells were harvested,
plated on a Matrigel layer in 2% FCS and observed for capillary
morphogenesis. CMs from GDF5-siRNA and control not-target-
ing siRNA-treated-MCF7 cells were also used in Matrigel sponge
assay angiogenesis. In order to evaluate the effectiveness of GDF5
silencing and its effect on uPAR expression, quantitative PCR was
performed with an Applied 7500 Fast apparatus using reagents
provided by the manufacturer (SYBR Green Master mix, Applied
Biosystems, CA, USA). Total mRNA was extracted and retro-
transcribed as described above. A primer pair (Forward: 59-
AGGCAACAGCAGCGTGAAGT-39; Reverse: 59-
GGTCATCTTGCCCTTTGTCAA-39) able to amplify a 76 bp
fragment from the human GDF5 cDNA, was designed with
Primer Express 3.0 software and purchased from Integrated DNA
Technologies (Belgium, EU). RNA amount was evaluated using
the DDCt method normalizing to 18 s RNA (Forward: 59-
CGGCTACCACATCCAAGGAA-39 and reverse 59-
GCTGGAATTACCGCGGCT-39). uPAR primers and cycling
conditions were as previously reported [39].
RT-PCR analysis of ALKs receptors
RT-PCR analysis of ALKs receptors was determined by an
internal-based semi-quantitative RT-PCR, using procedures
previously described [41]. The primers’ sequences, the size of
products and cycling profile are reported in Table 1. The reaction
products were analyzed by electrophoresis in 1% agarose gel
containing ethidium bromide and the amount of each amplifica-
tion product was determined by densitometer analysis.
Statistical analysis
Results are expressed as means 6 SD. Multiple comparisons
were performed by the Student test. Statistical significances were
accepted at p,0.05.
Table 1. PCR primers and cycling conditions.
Primer Sequence Size (bp) Cycling profile
ALK1 59-ATTACCTGGACATCGGCAAC-39 (sense) 214 94uC, 1 min; 59uC , 1 min; 72uC, 1 min;
35 cycles total
59-TTGGGCACCACATCATAGAA-39 (antisense)
ALK2 59-TCAGGAAGTGGCTCTGGTCT-39 (sense) 180 94uC, 1 min; 59uC , 1 min; 72uC, 1 min;
35 cycles total
59-CGTTTCCCTGAACCATGACT-39 (antisense)
ALK3 59-CGTTTCCCTGAACCATGACT-39 (sense) 137 94uC, 1 min; 59uC , 1 min; 72uC, 1 min;
35 cycles total
59-AGCCCTACATCATGGCTGAC-39 (antisense)
ALK5 59- ATCCCAAACAGATGGCAGAG-39 (sense) 178 94uC, 1 min; 59uC , 1 min; 72uC, 1 min;
35 cycles total
59- GGAGAGTTCAGGCAAAGC TG-39 (antisense)
ALK6 59-AAGTTACGCCCCTCATTC-39 (sense) 244 94uC, 1 min; 59uC , 1 min; 72uC, 1 min;
35 cycles total
59- TGATGTCTTTTGCTCTGC-39 (antisense)
GAPDH 59-CCACCCATGGCAAATTCCATGGCA-39 (sense) 598 94uC, 1 min; 56uC , 1 min;72uC, 1 min;
35 cycles total
59-TCTAGACGGCAGGTCAGGTCCACC-39 (antisense)
doi:10.1371/journal.pone.0050342.t001
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Results
A mutated TGFß gene inserted in an inducible vector
results in conditional expression of mature TGFß upon
transient transfection
Effects of TGFß overproduction on MCF7 cells. In order
to obtain a cell model recapitulating the increase of TGFß
expression/activation, a mutated TGFß gene (coding for activated
TGFß) was cloned under the control of a tetracycline-repressed
CMV promoter. Tet-Off MCF-7 cells were transiently transfected
with the inducible construct or the empty vector. Twenty-four
hours after transfection the medium was replaced with a serum-
free medium containing or not doxycyclin. The supernatants were
collected after five days and assayed for TGFß by western blot
analysis (figure 1, panel A). The western blot analysis revealed a
difference of about ten folds in the content of 12,5 kD TGFß
monomer in media from MCF7 cells transfected with TGFß
(MCFTß) with respect to the media from the mock transfected
sample (MCFM), and a difference of more than two folds was
observed with respect to the media from doxycycline-treated
TGFß expressing cells. The difference in TGFß content between
media from TGFß transfected cells treated with doxycycline and
media from mock transfected cells was bona fide due to residual
mature TGFß present inside the cells and to residual transcrip-
tional/translational activity; in fact, Western blot analysis (not
shown) demonstrated that TGFß precursor forms returned to the
basal level within 72 hours upon doxycycline treatment and,
therefore, that residual presence of TGFß in the presence of
doxycycline was not related to leakage of bad functioning of the
system. Results in agreement with those obtained with Western
blot were obtained by ELISA TGFß quantification in MCFM and
MCFTß media collected after five days from doxycycline
withdrawal. (figure 1, panel B).
Panel C of figure 1 shows that TGFß over-expression induced in
MCF7 nuclear translocation of vimentin [42], decrease of
cytoplasmic E-cadherin and increase of N-cadherin [43]. Panel
D shows the Western blotting of the relevant molecules. Further,
cell viability was not decreased (figure 1, panel E) and apoptosis
(evaluated by caspase-3 activation, figure 1, panel G) was not
increased by TGFß over-expression. MCF7 invasion of Matrigel-
coated filters resulted amplified (figure 1, panel F). Taken together,
all these features recapitulate several characteristics of an
epithelial-to-mesenchymal (EMT) transition.
Evaluation of the angiogenic effects of TGFß over-
expressing cells in vitro and in vivo
Inhibition by anti-TGFß peptides. MCFM and MCFTß-
dependent angiogenesis was evaluated in vitro by capillary
morphogenesis and in vivo by matrigel sponge assay. MVECs
were cultivated in CM of MCFM or MCFTß, in the presence or
absence of doxycycline (figure 2, panel A). On the basis of our
previous data of TGFß angiogenesis on MVECs [17], we diluted
CM of MCFTß to obtain a TGFß concentration of 1 ng/ml, the
most efficient in stimulating an angiogenic response in vitro. The
same concentration was used throughout the work in in vitro
experiments, and CM of MCFM was diluted accordingly. MCFTß
CM obtained in the absence of doxycycline (Dx2), produced a
marked increase in capillary-like networks formation already at
6 hours after treatment, with respect to media from MCFM.
Differences were maintained also after 18 h (not shown). CM from
cells treated with doxycycline (Dx+) were less efficient in capillary
morphogenesis promotion. Overall, these data indicate that TGFß
overproduction by MCF7 cells is associated with an increase of
capillary morphogenesis and that MCF7 cells used in this study are
not endowed with a relevant spontaneous pro-angiogenesis
activity. MVEC cells were exposed to MCFTß CM for 6–
18 hours after plating on Matrigel in the presence of p17, p144 or
a scramble peptide as a negative control (figure 2, bottom pictures
of panel A). According to its higher solubility in aqueous solution
with respect to P144 [17], the p17 inhibitor showed enhanced
antiangiogenic activity. The ability of TGFß to induce angiogen-
esis in vivo was evaluated in SCID mice by Matrigel sponge assay
(figure 2, panel B). A mix of Matrigel, MCF-7 transiently-
transfected cells and heparin was injected subcutaneously into the
flanks of SCID mice. In the absence of doxycycline (Dx2), mice
injected with MCFTß showed a marked increase in angiogenesis
with respect to mice injected with MCFM. The angiogenesis
increase was almost completely abolished by addition of doxycy-
cline in the injection mix (Dx+) (not shown), or in animals pre-
treated with i.p. injection of doxycycline for two days before the
Matrigel sponge and treated with doxycycline for the whole
duration of the experiment (shown in figure 2B). In view of its high
solubility, only the p17 decoy peptide was used in the Matrigel
sponge assay in SCID mice. p17 administration inhibited
MCFTß-dependent angiogenesis independently of the adminis-
tration protocol (addition to the injection mix or injected i.p.).
Angiogenesis under the described conditions was quantified by
measuring the haemoglobin content in Matrigel extracts (histo-
gram on the left of figure 2, panel C) and by counting vessels
within the plug by immunohistochemistry using anti-CD31
antibodies to identify endothelial cells (figure 2, panel B and
histogram on the right of figure 2, panel C).
Canonical TGFß signaling is activated in angiogenesis
promoted by TGFß-overexpressing cells
There are indications that EC from various sources may greatly
differ with regard to the expression pattern of the ALK type I
receptor sub-unit for the TGFß family ligands [44]. Therefore, we
have characterized by a semi-quantitative RT-PCR the ALK
expression of MVEC used in this study and have obtained the data
Figure 1. TGFß expression in transfected MCF7 cells. Effects of TGFß overproduction on MCF7 cells. Panel A. Western blot of
conditioned-media. MCFM: MCF7-Tet-Off transfected with the mock empty vector; MCFTß: MCF7-Tet-Off transfected with the mutated TGFß1-coding
sequence. The figure reports a typical experiment out of 4 replicas. On the right, molecular weight expressed in kDa; Dx = Doxycycline. Panel B. ELISA
kit determination of TGFß concentration in the culture medium of MCF7 in the same conditions as in panel A (4 different experiments performed in
triplicate). * p,0.05 (Student t-test), significantly different from mock. Panel C. Confocal microscopy showing distribution of vimentin, E-cadherin
and N-cadherin in MCFM and MCFTß. Original magnification:660. Panel D. Western blot of cell lysates. On the right, molecular weight expressed in
kDa. Tubulin: loading control. The figures report a typical experiment out of 4 replicas. Panel E. Kinetics of % vital cells obtained by using the WST-1
reagent. Data are shown as the mean 6SD obtained in 4 different experiments performed in triplicate in the reported conditions. Panel F. MCFM
and MCFTß cells Matrigel invasion in the Boyden chamber assay. Data are expressed as percent variations of invasive cells against the untreated
control, taken as 100%, 6SD, obtained in 4 different experiments performed in triplicate. * p,0.05 (Student t-test), significantly different from mock.
Panel G. Western blotting showing caspase activation. On the right, molecular weight expressed in kDa. Tubulin: loading control. The figure reports
a typical experiment out of 4 replicas.
doi:10.1371/journal.pone.0050342.g001
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Figure 2. In vitro and in vivo evaluation of MCF7-TGFß-induced angiogenesis. Panel A. MVECs were exposed for 6 hours to CM from
MCFTß or MCFM. Numbers on the upper right side indicate the percent field occupancy of capillary plexus (6SD), taking untreated MVECs incubated
in their own culture medium as 100%. Since the overall morphology did not substantially differ between 6 and 18 h after MVEC seeding (apart of a
better definition of tubule formation by capillary projections), quantification was performed at 6 h after seeding. Pictures show a typical out of 4
different experiments that gave similar results. Dx: Doxycycline. The bottom pictures of panel A show capillary morphogenesis of MVECs exposed to
CM of Dx2/MCFTß in the presence of p17 (+P17), p144 (+P144) or of a scrambled oligopeptide (+scr), respectively. * p,0.05 (Student t-test),
significantly different from mock. Panel B. Upper part: Matrigel sponges, containing 2.56106 MCFTß or MCFM, were recovered five days post
implantation in 4 mice, each one grafted with 2 different sponges. The anti-angiogenesis activity of p17 peptide was evaluated in the presence of
MCFTß. The figure shows a typical experiment out of 4 different experiments that gave similar results, upon systemic administration (i.p.) of the
peptide. Co-injecting p17 in the plug with MCFTß gave similar results (not shown). Dx: Doxycycline. Lower part: CD31 immunohistochemistry of
sponges in the same experimental conditions shown in the upper part. Panel C. On the left: haemoglobin contents6 SD versus MCFM +Dx taken as
100% in explanted specimes from 4 different experiments. On the right: % vascularization 6 SD in the same conditions. * p,0.05 (Student t-test),
significantly different versus the relevant control.
doi:10.1371/journal.pone.0050342.g002
Figure 3. Evaluation of ALK pattern and SMAD1/2/3/5 phosphorylation in MVECs. Panel A. RT-PCR showing ALK expression on 3 of the
MVEC cell lines used. GAPDH: loading control. Bp is shown on the right. The picture shows the results of a typical experiment out of 3 replicas. Panel
B. Quantification of ALK RNA as related to GAPDH. The histogram shows the results obtained in 3 different experiments performed in duplicate on
each MVEC cell line, 6 SD. * p,0.05 (Student t-test), significantly different among various ALK RNAs. Panel C. Western blots of total protein extracts
from MVECs exposed to CM of MCFM and MCFTß for 30 min and 120 min, respectively, in the presence or absence of P17. Western blots were
probed for phospho-SMAD1/5, SMAD5, phospho-SMAD2, SMAD2/3 and Tubulin (loading control) as indicated. Molecular weights are reported on the
right. Also in this case the picture shows the results of a typical experiment out of 3 replicas.
doi:10.1371/journal.pone.0050342.g003
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shown in figures 3A and 3B, an ALK pattern that may support
stimulation by almost all the TGFß family members. Activation of
the canonical EC TGFß signaling was investigated by assessing the
phosphorylation of SMAD1/5 and SMAD2/3 proteins, as well as
SMAD4 nuclear translocation. Aliquots of total protein extracts
from MVEC cells exposed for 2.5 hours to CM of cancer cells
were analyzed by Western blot probed for p-SMAD1/5 and p-
SMAD2 (figure 3C). While phosphorylation of SMAD2 was
evident at 30 min following addition of MCFTß CM, the amount
of phosphorylated SMAD1/5 occurred at 2 h after stimulation. p-
SMAD2 returned to basal levels 90 min after stimulation, while p-
SMAD1/5 appeared at 90 min following CM challenge (not
shown). Treatment with anti-TGFß p17 reduced the level of both
p-SMAD1/5 and p-SMAD2. It is known that, following
phosphorylation, SMAD2/3 and/or SMAD1/5 bind SMAD4,
giving origin to a complex which undergoes nuclear translocation
and triggers transcription of a series of genes relevant for TGFß
activity. Therefore, we investigated by confocal microscopy the
time course of SMAD4 subcellular distribution in MVECs
challenged with CM of MCFM and MCFTß (figure 4). A nuclear
pattern of SMAD4 became evident 30 minutes after stimulation
only with MCFTß CM, concomitant with SMAD2 phosphoryla-
tion. Such a pattern was absent in each condition 60 minutes after
stimulation, but nuclear localization of SMAD4 became again
evident after 2 hours, concomitant with SMAD1/5 phosphoryla-
tion, only in MVECs treated with MCFTß CM. As expected,
treatment with TGFß inhibitor p17 prevented SMAD4 nuclear
translocation.
TGFß pathways are activated in endothelial cells
challenged with conditioned-medium of TGFß-
overexpressing cells and are controlled by anti-TGFß
peptides
In order to study the pattern of gene activation expressed by
MVECs treated with medium of conditionally transfected MCF7,
a qPCR based assay was used for quantitative profiling of a set of
94 preselected genes related to TGFß pathways. Besides direct
challenge of MVEC with recombinant TGFß (1 ng/ml), three
different experiments (MVECs stimulation with CM from MCFM
and MCFTß, in the absence and in the presence of p17 peptide
inhibitor) were performed. In order to derive biological meaning
from the differentially regulated genes, we performed the
functional classification of all the involved genes on the basis of
information from the Gene Ontology database (Molecular
Function, Biological Process and Cellular Component) and from
data collected in the scientific literature. Only genes involved in
the angiogenesis process were selected. Figure 5A shows that, at
6 hours, stimulation of MVECs with exogenously added recom-
binant TGFß induced a more than forty fold over-expression of
the Growth and Differentiation Factor-5 (GDF5), a pro-angio-
genic BMP [45]. When MVECs were stimulated for 6 hours with
CM from MCFM and MCFTß, in the absence and in the
presence of p17 peptide inhibitor (figure 5B), we observed a
striking up-regulation of both GDF5 and of BMP7, another BMP
whose co-operative role in TGFß angiogenesis has been empha-
sized [46]. The p17 peptide completely reverted over-expression of
each relevant molecule, showing that expression of up-regulated
BMPs is dependent on TGFß stimulation of MVECs. Figure 5C
shows a quantitative PCR indicating that: a) stimulation of
MVECs with MCFTß CM up-regulates both GDF5 and uPAR
expression; b) an anti-GDF5 siRNA down-regulates both GDF5
and uPAR expression either in the absence or in the presence of
MCFTß CM stimulation. Stimulation with recombinant TGFß
gave similar results (not shown). Figure 5D shows the Western
blotting with anti-GDF5 IgG (5 mg/ml) and anti-uPAR M2
polyclonal antibody (5 mg/ml) of aliquots (100 mg) of MVEC
lysates under control conditions, and after stimulation with
MCFTß CM, in the absence (control) or in the presence of
lipofectamine alone, of lipofectamine containing not-targeting
RNA (siNT, not-targeting) and of lipofectamine containing anti-
GDF5 siRNA. The results shown in figure 5C show that uPAR
up-regulation, previously shown to drive TGFß-dependent angio-
genesis [17], is regulated by TGFß-dependent GDF5 up-regula-
tion. Figure 6A shows capillary morphogenesis experiments
performed with untreated MVECs (taken as 100%), and with
Figure 4. SMAD4 nuclear translocation. Numbers on the left
indicate the elapsed time (hours) after addition of MCFM and MCFTß
CM to MVEC. +P17: results obtained in the presence of the TGFß
inhibiting peptide p17. The data show a typical experiment out of 3
replicas that gave similar results.
doi:10.1371/journal.pone.0050342.g004
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MVECs challenged by MCFTß CM, in the presence of irrelevant
IgG, of anti-GDF5 IgG, of siNT (not-targeting) and of siGDF5.
Both anti-GDF5 treatments inhibited MCFTß CM-induced
capillary morphogenesis. Similar results (not shown) were obtained
in capillary morphogenesis experiments upon stimulation with
exogenously added recombinant TGFß. Interestingly, antibodies
and siRNA targeting BMP7 did not inhibit Tet-Off conditioned-
media-dependent capillary morphogenesis of MVEC (figure 6A),
which implies GDF5 as the only BMP positively involved in
TGFß-dependent angiogenesis and uPAR up-regulation in
MVECs. Taken together, these data strongly indicate that
TGFß-dependent MCF7 angiogenesis depends on induction of
GDF5 in MVECs, which, in turn, up-regulates uPAR expression.
On these basis we have performed in vivo Matrigel sponge assays
(figure 6B), co-injecting in C57/BL6 male mice Matrigel
containing CM of MCFTß cells obtained after doxycycline
subtraction, with or without GDF5-siRNA, combined with
DharmaFECT, siNT combined with DharmaFECT, or Dharma-
FECT alone (transfection reagent, TR). Also anti-GDF5 antibod-
ies were used to block the GDF5 effects (same figure) . Results
clearly show that, even in this in vivo setting, silencing or inhibition
of GDF5 inhibits TGFß-dependent MCF7 angiogenesis.
Discussion
In this paper we have shown that TGFß produced by breast
cancer cells induces in endothelial cells GDF5 expression, which in
turn stimulates angiogenesis both in vitro and in vivo. Angiogenesis
activation is very rapid and the involved mechanism is totally
opposed to the old and controversial dogma about the AKL5/
ALK1 balance. We have inserted in human MCF7 breast cancer
cell line a mutated TGFß gene in a tetracycline-repressible vector
in order to obtain conditional expression of mature TGFß in the
absence of tetracycline upon transient transfection. Transfected
MCF7 cells expressed several characteristics of the EMT and did
not show viability decrease or caspase-3 activation. The condi-
tioned-medium of TGFß-over-expressing MCF7 cells (MCFTß)
stimulated angiogenesis in vitro and in vivo, which was inhibited by
TGFß inhibitor peptides upon local or systemic administration.
We have also shown early activation of TGFß SMAD2/3,
followed by activation of SMAD1/5 signaling in MVEC by
Figure 5. TGFß-dependent gene activation in MVECs. Panel A. Activation of pro-angiogenic genes following 6 h MVEC stimulation with
exogenously added recombinant TGFß (1 ng/ml). BMP7, bone morphogenetic protein-7; GDF5, growth and differentiation factor-5. Data shown were
obtained in 3 different experiments performed in double, and are expressed as average value 6SD. * p,0.05 (Student t-test). Panel B. Activation of
pro-angiogenic genes following 6 h MVEC stimulation with CM of MCFM and MCFTß cells in the absence and in the presence of peptide p17. White
columns: fold change of gene expression under stimulation with Dx2/MCFTß-CM with respect to MCFM-CM, assumed as value 1. Grey columns: the
same of white columns, in the presence of p17. Data shown were obtained in 3 different experiments performed in double, and are expressed as
average value 6SD. * p,0.05 (Student t-test) with respect to values obtained with MCFM CM; ** p,0.05 in the presence of the inhibiting peptide
with respect to stimulation by Dx2/MCFTß-CM. Panel C. Quantitative PCR of GDF5 and uPAR in control MVECs and in MVECs stimulated with 1 ng/
ml TGFß. non targ: not-targeting siRNA; siGDF5, siRNA anti-GDF5. * p,0.05 (Student t-test) with respect to values obtained with not-targeting siRNA.
Panel D. Western blotting of MVEC lysates (100 mg/lane), under control conditions (control) and following stimulation with 1 ng/ml TGFß alone
(TGFß), TGFß+lipofectamine (lipo), TGFß+not targeting siRNA (siNT) and TGFß+GDF5-targeting siRNA (siDGF5). The primary antibodies were anti-
GDF5 IgG and M2 polyclonal anti-uPAR antibody. Tubulin, loading control. Molecular weights are reported on the right.
doi:10.1371/journal.pone.0050342.g005
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MCFTß cells, along with SMAD4 nuclear translocation and
transcription of pro-angiogenic molecules, including uPAR and
GDF5. All these events underwent anti-TGFß peptides-dependent
inhibition. Thus MCF7 overproduction of TGFß and the
subsequent chain of pro-angiogenic effects may be controlled by
an efficient TGFß antagonization. Our data, showing phosphor-
ylation of both SMAD2/3 and SMAD1/5 in MVECs upon
stimulation with TGFß, are in agreement with the reported TGFß
transduction pathways in EC [14,46]. The analysis of a set of
genes related to TGFß pathway has allowed to show for the first
time that the most relevant changes of gene expression induced in
MVEC by breast carcinoma cells conditionally induced to over-
express TGFß, included some members of the BMPs family. BMPs
are intercellular signaling molecules with multiple functions during
development and differentiation [47,48]. BMPs belong to the
TGFß superfamily of growth factors and bind to heteromeric
transmembrane serine/threonine kinase receptors [48–51]. Such
interaction triggers downstream signalling cascades that are strictly
dependent on the sub-family of the involved BMPs and that
involve angiogenesis for several BMPs [23,29,51]. Angiogenesis is
a multistep process that can be divided in two phases. During the
initial ‘‘activation’’ phase, the perivascular basement membrane is
degraded, endothelial cells migrate in the extracellular space,
proliferate, form capillary sprouts and organize in tubular-like
Figure 6. TGFß/GDF5-dependent angiogenesis in vitro and in vivo. Panel A. Capillary morphogenesis experiments in control MVECs
(untreated), upon MCFTß CM stimulation alone, and in the presence of irrelevant IgG (+ Irrel IgG), 5 mg/ml anti-GDF5 antibody (anti-GDF5), not-
targeting siRNA (siNT), GDF5-targeting siRNA (siGDF5), 5 mg/ml anti-BM7 antibody (anti BMP7), BMP7-targeting siRNA (siBMP7). Panel B.
Representative experiment of siGDF5-dependent and anti-GDF5 antibody-dependent inhibition of angiogenesis in the Matrigel sponge model in
mice. Panel C. On the left: angiogenesis in the sponges was quantified by evaluating the haemoglobin content of each sponge. On the right: %
vascularization 6 SD in the same conditions. Images were acquired with the ZEISS SR Stemi stereomicroscope. TR: transfection reagents alone; siNT:
not-targeting siRNA. Results are the mean of three experiments (three animal for each condition, two Matrigel sponges in each animal). Graphs are
shown as mean 6 SD; * p,0.05 (Student t-test) with respect to both transfection reagents alone (TR) and not-targeting siRNA (siNT).
doi:10.1371/journal.pone.0050342.g006
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structures. In the subsequent ‘‘maturation-stabilization’’ phase EC
stop invasion and proliferation, the basement membrane is rebuilt
and smooth muscle cells/pericytes are recruited in order to
surround neo-vessels, thus reconstituting vessel wall integrity.
Recent observations clearly emphasize the emerging role of BMPs
in angiogenesis [23,52], leading to the proposal of a BMPs balance
which controls angiogenesis activation and maturation [52]. The
proposed model distinguishes among the BMP2/4, the BMP5/6/
7 and the GDF5/6/7 subgroups (which controls the activation
phase of angiogenesis) from the BMP9/10 subgroup (which
regulates only the maturation phase). Among the angiogenesis-
related BMPs, only BMP9/10 signalling involves the ALK1
pathway, while all the other subfamilies signal through ALK2/3/
6. In all the cases, pathway activation involves SMAD1/5/8
phosphorylation and SMAD4 nuclear translocation, which regu-
lates transcription of target genes involved with angiogenesis
activation/maturation. Endoglin and betaglycan are co-receptors,
expressed in EC, which regulate the availability of BMPs to type I
and type II receptors. Here we have shown that direct stimulation
of MVEC by MCFTß CM and exogenous TGFß is characterized
by a strong over-production of GDF5, which up-regulates uPAR
in MVEC and stimulates the formation of capillary networks in
vitro. These data are in agreement with our previous results
showing that uPAR up-regulation is mandatory in TGFß-
dependent angiogenesis [17]. MVEC used in this work express
the type-I receptors ALK1/2/3/5/6 and are therefore available to
interact with every member of the TGFß/BMP superfamily,
including the ALK2/3/6-related GDF5. GDF5 silencing impaired
MCFTß-CM-dependent angiogenesis in vitro and in vivo. GDF5
was the first BMP reported to have a role in angiogenesis. GDF5
enhances angiogenesis in the chorio-allantoic membrane (CAM)
assay and in the rabbit cornea assay [45], by increasing aortic EC
migration but not their proliferation. On the other side, in the
context of conditional TGFß over-production by MCF7 cells, we
have observed that MVEC stimulation results into overproduction
not only of GDF5, but also of BMP7. Both these molecules have
been recognized to be implicated in angiogenesis [45,46].
However, validation of our microarray data obtained by Western
blotting, specific antibodies-inhibition, siRNA and capillary
morphogenesis, point to GDF5 as the only BMP involved in
MCF7-mediated TGFß-dependent angiogenesis in our model
system. At present we are unable to explain why only GDF5 is
involved in angiogenesis stimulation. Since BMP7 has been shown
to be pro-angiogenic in synergy with TGFß but only at very high
concentrations of both molecules [46], we hypothesize that the
concentrations obtained under our experimental conditions do not
reach the threshold levels required to synergize in angiogenesis
promotion. Recent papers have clearly shown that genetic and
pharmacological targeting of ALK1 impairs tumor angiogenesis
and growth by impairment of BMP9 signalling [32,53]. On the
basis of our data on GDF5-mediated TGFß induction of
angiogenesis, it is now possible to suggest a putative series of
events triggered by the initial interaction of TGFß with its
receptors and culminating with a GDF5-dependent activation of
angiogenesis. Our data, albeit obtained in an artificial TGFß-
dependent angiogenesis tumor model, provide the first description
of an activation of these events in EC as an effect of conditional
TGFß-overexpression in cancer cells. The evidence that anti-
TGFß peptides treatment efficiently blocks TGFß angiogenesis
even upon systemic administration, renders these molecules
particularly interesting for a possible pharmacological control of
mammary cancer TGFß-switch. However, it is common experi-
ence that peptides so far have not done well in clinical translation.
Antibody targeting has much better characteristics in vivo and in
patients than do most peptides, suggesting this could be an
interesting approach. Targeting GDF5 may also leave intact some
of the anti-tumor activities of TGFß, while blocking pro-tumor
activities.
Conclusions
Conditional TGFß production by MCF7 breast cancer cells
induces angiogenesis both in vitro and in vivo. In our model,
angiogenesis activation depends on TGFß-dependent production
of growth and differentiation factor-5 (GDF5) in target endothelial
cells, a mechanism that is different from the old and controversial
dogma about the AKL5/ALK1 balance. The GDF5-dependent
pro-angiogenic effects of TGFß are controlled by anti-TGFß
peptides and anti-GDF5 antibodies. These preclinical data provide
a basis to develop researches aimed to validate our observations in
breast tumors with the aim to use anti TGFß–peptides and anti-
GDF5 antibodies as possible therapeutic tools for TGFß/GDF5–
dependent breast cancer angiogenesis.
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